In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

Purpose: COVID-19 has become global threaten. CT acts as an important method of 60 diagnosis. However, human-based interpretation of CT imaging is time consuming. 61 More than that, substantial inter-observer-variation cannot be ignored. We aim at 62 developing a diagnostic tool for artificial intelligence (AI)-based classification of CT 63 images for recognizing COVID-19 and other common infectious diseases of the lung. 64 Experimental Design: In this study, images were retrospectively collected and 65 prospectively analyzed using machine learning. CT scan images of the lung that show 66 or do not show COVID-19 were used to train and validate a classification framework 67 based on convolutional neural network. Five conditions including COVID-19 68 pneumonia, non-COVID-19 viral pneumonia, bacterial pneumonia, pulmonary 69 tuberculosis, and normal lung were evaluated. Training and validation set of images 70 were collected from Wuhan Jin Yin-Tan Hospital whereas test set of images were 71 collected from Zhongshan Hospital Xiamen University and the fifth Hospital of 72 Wuhan. 73 Results: Accuracy, sensitivity, and specificity of the AI framework were reported. For 74 test dataset, accuracies for recognizing normal lung, COVID-19 pneumonia, 75 non-COVID-19 viral pneumonia, bacterial pneumonia, and pulmonary tuberculosis 76 were 99.4%, 98.8%, 98.5%, 98.3%, and 98.6%, respectively. For the test dataset, 77 accuracy, sensitivity, specificity, PPV, and NPV of recognizing COVID-19 were 78 98.8%, 98.2%, 98.9%, 94.5%, and 99.7%, respectively. 79 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Deep Learning-Based Recognizing COVID-19 Deep Learning-Based Recognizing COVID-19 and other Common Infectious Diseases of the Lung by Chest CT 2 Scan Images

Ten years after the severe acute respiratory syndrome epidemic, a second coronavirus, the Middle East respiratory syndrome coronavirus (MERS-CoV), has been identified as the cause of a highly lethal pneumonia in patients in the Middle East and in travelers from this region. Over the past 9 months, since the virus was first isolated, much has been learned about the biology of the virus. It is now clear that MERS-CoV is transmissible from person to person, and its close relationship with several bat coronaviruses suggests that these animals may be the ultimate source of the infection. However, many key issues need to be addressed, including identification of the proximate, presumably zoonotic, source of the infection, the prevalence of the infection in human populations, details regarding clinical and pathological features of the human infection, the establishment of a small rodent model for the infection, and the virological and immune basis for the severe disease observed in most patients. Most importantly, we do not know whether a MERS-CoV epidemic is likely or not. Infection with the virus has so far resulted in only 91 cases and 46 deaths (as of 29 July 2013), but it is nonetheless setting off alarm bells among public health officials, including Margaret Chan, Director-General of the World Health Organization, who called MERS-CoV "a threat to the entire world." This article reviews some of the progress that has been made and discusses some of the questions that need to be answered. Citation Perlman S. 2013. The Middle East respiratory syndrome-how worried should we be? mBio 4(4):e00531-13.
The Middle East Respiratory Syndrome-How Worried Should We Be? A NOVEL VIRUS IS IDENTIFIED IN SAUDI ARABIA

a r t i c l e i n f o a b s t r a c t Article history: Flos Chrysanthemi (the flower of Chrysanthemum morifolium Ramat.) is widely used in China as a metabolites of luteolin in vivo by cathechol-O-methyltransferase (COMT). However, there was lack of pharmacokinetic information of chrysoeriol and diosmetin after oral administration of Flos Keywords: Chrysanthemi extract (FCE). The present study aimed to develop an HPLC-UV method for Luteolin simultaneous determination of rat plasma concentration of luteolin, apigenin, chrysoeriol and Chrysoeriol diosmetin and utilize it in pharmacokinetic study of the four compounds after orally giving FCE to Diosmetin rats. The method was successfully validated and applied to the pharmacokinetic study when oral Pharmacokinetics administration of FCE to rats with or without co-giving a COMT inhibitor, entacapone. Chrysoeriol Flos Chrysanthemi and diosmetin were detected in rat plasma after oral administration of FCE and their Catechol-O-methyltransferase (COMT) concentrations were significantly decreased after co-giving entacapone. Furthermore, AUC of luteolin was significantly increased by entacapone, while that of chrysoeriol was decreased by entacapone, which revealed COMT might play an important role in the disposition of luteolin in rats after dosing of FCE. In conclusion, a sensitive, accurate and reproducible HPLC-UV method for simultaneous determination of luteolin, apigenin, chrysoeriol and diosmetin in rat plasma were developed, pharmacokinetics of chrysoeriol and diosmetin combined with luteolin and apigenin were characterized after oral administration of FCE to rats, which gave us more information on pharmacokinetics and potential pharmacological effects of FCE in vivo.

Pharmacokinetic study of luteolin, apigenin, chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract in rats bioactive components in Flos Chrysanthemi, and chrysoeriol and diosmetin are two methylated